Passage Bio, INC. (PASG) — 8-K Filings

8-K Filings (18)

• Passage BIO, Inc. Files 8-K — Apr 20, 2026 Risk: low
  Passage BIO, Inc. filed an 8-K on April 20, 2026, to disclose information under Regulation FD. The filing includes exhibits such as financial statements and oth
• Passage BIO Announces Board and Executive Changes — Sep 18, 2025 Risk: medium
  Passage BIO, Inc. announced on September 16, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported
• Passage BIO, Inc. Files 8-K Report — Jul 29, 2025 Risk: medium
  On July 28, 2025, Passage BIO, Inc. filed an 8-K report detailing an "Other Event." The filing does not disclose specific details about the event itself, but it
• Passage BIO, Inc. Files 8-K with Corporate Updates — Jul 14, 2025 Risk: medium
  Passage BIO, Inc. filed an 8-K on July 14, 2025, reporting events as of July 10, 2025. The filing indicates material modifications to security holder rights, am
• Passage BIO Files 8-K — Jun 23, 2025 Risk: low
  Passage BIO, Inc. filed an 8-K on June 23, 2025, reporting other events and financial statements. The filing does not contain specific details about new materia
• Passage BIO, Inc. Reports on Security Holder Vote — May 30, 2025 Risk: medium
  Passage BIO, Inc. filed an 8-K on May 30, 2025, reporting on a matter submitted to a vote of its security holders on May 28, 2025. The filing does not disclose
• Passage BIO Faces Delisting Concerns — Jan 31, 2025 Risk: high
  Passage BIO, Inc. filed an 8-K on January 31, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer o
• Passage BIO, Inc. Files 8-K on Operations and Disposals — Jan 10, 2025 Risk: medium
  Passage BIO, Inc. filed an 8-K on January 10, 2025, reporting events as of January 8, 2025. The filing pertains to results of operations, cost associated with e
• Passage BIO Files 8-K — Oct 24, 2024 Risk: low
  Passage BIO, Inc. filed an 8-K on October 24, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spec
• Passage BIO, Inc. Files 8-K Report — Sep 16, 2024 Risk: low
  On September 16, 2024, Passage BIO, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, including financial stat
• Passage BIO Appoints New CMO and Board Member — Sep 10, 2024 Risk: medium
  Passage BIO, Inc. announced on September 9, 2024, changes in its executive team and board of directors. Specifically, Dr. Michael J. Boyle has been appointed as
• Passage BIO Reports Material Impairment — Sep 6, 2024 Risk: medium
  Passage BIO, Inc. reported a material impairment on September 4, 2024, related to its gene therapy programs. The company recognized a significant impairment cha
• Passage BIO Faces Delisting Notice — Aug 2, 2024 Risk: high
  Passage BIO, Inc. filed an 8-K on August 1, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is incorporated in
• Passage BIO, Inc. Files 8-K: Material Agreement, Financials, Officer Changes — Aug 1, 2024 Risk: medium
  Passage BIO, Inc. announced on July 26, 2024, that it entered into a material definitive agreement. The company also reported its results of operations and fina
• Passage BIO Files 8-K — Jul 16, 2024 Risk: low
  Passage BIO, Inc. filed an 8-K on July 16, 2024, to report on other events and financial statements. The filing does not contain specific details about new mate
• Passage BIO Reports on Shareholder Vote Matters — May 22, 2024 Risk: low
  Passage BIO, Inc. filed an 8-K on May 21, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain details about spec
• New Mountain Capital to Acquire Passage BIO for $1.4B — Feb 29, 2024 Risk: medium
  Passage BIO, Inc. announced on February 29, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of private equity firm New Moun
• Passage BIO Confirms Nasdaq Listing for Common Stock — Jan 5, 2024
  Passage BIO, Inc. filed an 8-K on January 5, 2024, to disclose that its Common Stock, with a $0.0001 Par Value Per Share, is registered on The Nasdaq Stock Mark

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX